Genistein prevents the decrease in ganglioside levels induced by amyloid-beta in the frontal cortex of rats

Neurol Res. 2022 Jul;44(7):598-604. doi: 10.1080/01616412.2021.2024731. Epub 2022 Jan 21.

Abstract

Objectives: In this study, an in vivo model of Aβ toxicity was used to investigate the effects of this peptide and the treatment with genistein on the lipid composition (gangliosides, phospholipids and cholesterol) in the frontal cortex of rats.

Methods: Male Wistar rats received bilateral intracerebroventricular infusions of Aβ1-42 (2 nmol) and genistein 10 mg/kg orally for 10 days. Frontal cortex was homogenized with chloroform:methanol for lipid extraction and ganglioside, phospholipid and cholesterol levels were evaluated.

Results: The Aβ-infused animals showed a significant decrease in ganglioside concentration and relative reduction of GD1b and GQ1b species. Treatment with genistein prevented the decrease in ganglioside levels. Phospholipid and cholesterol contents did not show significant differences.

Discussion: Considering the roles of gangliosides on neuronal function, findings described here can contribute to the knowledge of the potential neuroprotective mechanisms of genistein against Aβ-induced alterations in the frontal cortex of rats and provide a novel view in the multifaceted scenario associated with its beneficial effects.

Keywords: Alzheimer’s disease; amyloid-beta; cell membrane; genistein; lipids; neuroprotection.

MeSH terms

  • Amyloid beta-Peptides* / toxicity
  • Animals
  • Cholesterol / chemistry
  • Frontal Lobe* / chemistry
  • Gangliosides* / chemistry
  • Genistein* / pharmacology
  • Male
  • Peptide Fragments / toxicity
  • Phospholipids / chemistry
  • Rats
  • Rats, Wistar

Substances

  • Amyloid beta-Peptides
  • Gangliosides
  • Peptide Fragments
  • Phospholipids
  • Cholesterol
  • Genistein